Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
2011 · Aging · 686 citations
https://doi.org/10.18632/aging.100296
M
Marco Donia
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
501
Papers
14.1K
Citations
56
h-index
142
i10-index
Marco Donia is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 56, co-authored 426 publications.
ORCID: 0000-0003-4966-9752Papers by this author
worksMutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
2017 · Nature Communications · 480 citations
https://doi.org/10.1038/s41467-017-01460-0
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
2016 · Science · 443 citations
https://doi.org/10.1126/science.aaf2288
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
2020 · Annals of Oncology · 229 citations
https://doi.org/10.1016/j.annonc.2020.07.004
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
2021 · Nature Medicine · 199 citations
https://doi.org/10.1038/s41591-021-01544-x
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
2017 · Nature Communications · 165 citations
https://doi.org/10.1038/s41467-017-00786-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat